Europe
Company scores high for having a culture of diversity & belonging and work-life balance
Phase I clinical trial to evaluate safety and tolerability of ATR-002 in healthy volunteers
Probiodrug AG announced today its first quarter business update for the period ending March 31, 2019.
Pharming Group N.V. presents its (unaudited) interim financial report for the first quarter ended 31 March 2019.
The Institute of Cancer Research (ICR) in London, UK, is investing an initial £75 million to create a global center in what it is calling anti-evolution therapies for cancer.
Evotec SE announced today that its management will be presenting at and attending the following upcoming conferences:
Promore Pharma AB (publ) publishes its Interim report for the first quarter 2019 at 13.00 CET on 21 May 2019.
Pharma and biotech companies from across the globe provide business and pipeline updates, with news from Gecko, ValGenesis, NeuClone, Zymeworks, and more.
The 96-Week data showed continued efficacy of GS010 two years after injection, with best-corrected visual acuity (BCVA) holding a clinically meaningful improvement over baseline.
Today, Civica Rx announced it had inked a product supply agreement with Xellia Pharmaceuticals, where Xellia will manufacture essential antibiotics, including Vancomycin and Daptomycin, for Civica’s members.
PRESS RELEASES